Funder: Children's Tumor Foundation
Due Dates: January 4, 2027 (LOI opens) | February 1, 2027, 4:00 p.m. EST (LOI deadline) | September 1, 2027 (Award start)
Funding Amounts: Up to $200,000 total over two years, inclusive of up to 10% indirect costs
Summary: Supports clinical research on treatments, interventions, and disease management to improve health outcomes and everyday functioning for people with neurofibromatosis.
Key Information: Full applications are by invitation after LOI review; IRB approval is required before award activation.
Description
The Children's Tumor Foundation’s Clinical Research Award (CRA) supports investigation of new treatments, interventions, and management approaches for neurofibromatosis type 1 and all types of schwannomatosis. The program prioritizes bold, forward-thinking solutions that could improve everyday functioning and new directions in disease management likely to lead to larger studies and additional external funding.
Supported work can include prospective or retrospective clinical studies, pilot clinical trials, correlative investigations alongside ongoing trials, and molecular, imaging, or genetic biomarker studies. Patient-reported outcomes, real-world evidence, and observational studies are also within scope, including natural history, disease burden, risk stratification, treatment effects, and clinical heterogeneity associated with genetic, environmental, or biological factors.
